{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:27Z","timestamp":1786119207013,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/bor.0b013e328325bd94","type":"journal-article","created":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T03:25:26Z","timestamp":1235359526000},"page":"143-149","source":"Crossref","is-referenced-by-count":44,"title":["Update on emerging urate-lowering therapies"],"prefix":"10.1097","volume":"21","author":[{"given":"Saima","family":"Chohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210128","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Gout","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-10-20210128","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia among older adults in a managed care population","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"R3-10-20210128","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Arromdee","year":"2002","journal-title":"J Rheumatol"},{"key":"R4-10-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.rdc.2006.03.002","article-title":"Epidemiology of crystal arthropathy","volume":"32","author":"Choi","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"R5-10-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ncprheum0556","article-title":"The changing epidemiology of gout","volume":"3","author":"Roddy","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R6-10-20210128","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/ajkd.2002.33911","article-title":"The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988\u20131994","volume":"40","author":"Kramer","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R7-10-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez- Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"R8-10-20210128","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R9-10-20210128","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R10-10-20210128","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-10-20210128","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum Arthritis Care Res"},{"key":"R12-10-20210128","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology"},{"key":"R13-10-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R15-10-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/BOR.0b013e3282f54d03","article-title":"Can we make gout management more successful now?","volume":"20","author":"Becker","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"R16-10-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.bor.0000209434.82096.1f","article-title":"Recent developments in diet and gout","volume":"18","author":"Lee","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"R17-10-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R18-10-20210128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/BOR.0b013e3282f524a2","article-title":"Lifestyle and gout","volume":"20","author":"Hak","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"R19-10-20210128","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/art.21105","article-title":"The effects of vitamin C supplementation on serum concentrations of uric acid","volume":"52","author":"Huang","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R20-10-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.rdc.2006.02.005","article-title":"Hyperuricemia and associated diseases","volume":"32","author":"Becker","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"R21-10-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"R22-10-20210128","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interests of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"R23-10-20210128","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using antihyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R24-10-20210128","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.rhu.0000147049.12220.32","article-title":"Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting","volume":"10","author":"Riedel","year":"2004","journal-title":"J Clin Rheumatol"},{"key":"R25-10-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"R26-10-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacol"},{"key":"R27-10-20210128","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R28-10-20210128","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"R29-10-20210128","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"R30-10-20210128","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1081\/NCN-200027372","article-title":"Febuxostat (TMX-67), a novel, nonpurine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers","volume":"23","author":"Becker","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"Suppl 2","key":"R31-10-20210128","first-page":"269","article-title":"Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyperuricemia, and their pharmacokinetic profiles in humans","volume":"32","author":"Hoshide","year":"2003","journal-title":"Drug Metab Rev"},{"key":"R32-10-20210128","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel nonpurine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"R33-10-20210128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new selective nonpurine inhibitor of xanthine oxidase, in subjects with renal impairment","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"R34-10-20210128","first-page":"4029","article-title":"A phase 3 randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout [abstract]","volume":"58","author":"Becker","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R35-10-20210128","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: five-year findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"},{"key":"R38-10-20210128","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in refractory gout, and induction of antibody against poly(ethylene) glycol(PEG), in a phase 1 trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R39-10-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R40-10-20210128","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R41-10-20210128","first-page":"S400","article-title":"Efficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): results from GOUT 1 and GOUT2 [abstract]","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R42-10-20210128","first-page":"S176","article-title":"Tophus response to pegloticase (PGL) therapy: pooled results of GOUT1 and GOUT2 PGL phase 3 randomized, doubleblind, placebo-controlled trials [abstract]","volume":"58","author":"Baraf","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R43-10-20210128","first-page":"S178","article-title":"Improvement in health-related quality of life (HRQL) and disability index in treatment failure gout (TFG) after pegloticase (PGL) therapy: pooled results from GOUT1 and GOUT2, phase 3 randomized, double blind, placebo (PBO)-controlled trials [abstract]","volume":"58","author":"Edwards","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R44-10-20210128","first-page":"S880","article-title":"Immunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT1 and GOUT2, PGL phase 3, randomized: double blind, placebo controlled trials [abstract]","volume":"58","author":"Becker","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e328325bd94","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:44:30Z","timestamp":1786038270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200903000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328325bd94","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}